09:10 AM EDT, 09/30/2024 (MT Newswires) -- INmune Bio ( INMB ) said Monday it closed the enrollment of a phase 2 trial involving patients with early Alzheimer's Disease and elevated neuroinflammation.

INmune said it determined that they've enrolled enough patients to meet the study's target of 201 individuals, which will be evaluated with the company's investigational XPro treatment.

Price: 5.50, Change: +0.28, Percent Change: +5.36